Baseline prostate-specific antigen testing at a young age

European Urology

Volumn 61, Issue 1, 2012, Pages 1-7

  Loeb, Stacy ^a   Carter, H Ballentine ^b   Catalona, William J ^c   Moul, Judd W ^d   Schroder, Fritz H ^e  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Baseline; Prognosis; Prostate specific antigen; Screening; Young age

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; HUMAN; MALE; METASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ADULT; AGE FACTORS; AGED; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 82255162851     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.067     Document Type: Review

References (55)

1. M.J. Barry Screening for prostate cancer - the controversy that refuses to die N Engl J Med 360 2009 1351 1354
2. L.T. Klein, and F.C. Lowe The effects of prostatic manipulation on prostate-specific antigen levels Urol Clin North Am 24 1997 293 297 (Pubitemid 27169253)
3. L.L. Banez, R.J. Hamilton, and A.W. Partin Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer JAMA 298 2007 2275 2280 (Pubitemid 350146217)
4. S. Loeb, H.B. Carter, and P.C. Walsh Single nucleotide polymorphisms and the likelihood of prostate cancer at a given prostate specific antigen level J Urol 182 2009 101 104 discussion 105
5. J. Gudmundsson, S. Besenbacher, and P. Sulem Genetic correction of PSA values using sequence variants associated with PSA levels Sci Transl Med 2 2010 1 9
6. R.J. Hamilton, K.C. Goldberg, E.A. Platz, and S.J. Freedland The influence of statin medications on prostate-specific antigen levels J Natl Cancer Inst 100 2008 1511 1518
7. S. Loeb, D.W. Chan, and L. Sokoll Prostate specific antigen assay standardization bias could affect clinical decision making J Urol 180 2008 1959 1962 discussion 1962-3
8. National Cancer Institute Surveillance Epidemiology and End Results (SEER) program. SEER Web site. http://www.seer.cancer.gov.
9. K.A. Roehl, S.E. Eggener, and S. Loeb Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results Urol Oncol 24 2006 465 471 (Pubitemid 44810008)
10. J.A. Efstathiou, M.H. Chen, and W.J. Catalona Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality Urology 68 2006 342 347 (Pubitemid 44202546)
11. G. Aus, S. Bergdahl, P. Lodding, H. Lilja, and J. Hugosson Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer - results from a prospective, population-based randomized controlled trial Eur Urol 51 2007 659 664 (Pubitemid 46110933)
12. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
13. G.L. Andriole, E.D. Crawford, and R.L. Grubb III Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
14. E.D. Crawford, R. Grubb 3rd, and A. Black Comorbidity and mortality results from a randomized prostate cancer screening trial J Clin Oncol 29 2011 355 361
15. J. Hugosson, S. Carlsson, and G. Aus Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
16. American Cancer Society recommendations for prostate cancer early detection. American Cancer Society Web site. http://www.cancer.org/Cancer/ ProstateCancer/MoreInformation/ProstateCancerEarlyDetection/prostate-cancer- early-detection-acs-recommendations.
17. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;149:185-91.
18. L.S. Lim, and K. Sherin Screening for prostate cancer in U.S. men ACPM position statement on preventive practice Am J Prev Med 34 2008 164 170
19. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
20. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. NCCN Web site. http://www.nccn.org/professionals/physician-gls/ pdf/prostate-detection.pdf.
21. Prostate-Specific Antigen Best Practice Statement: 2009 update. American Urological Association Web site. http://www.auanet.org/content/media/psa09.pdf.
22. J.W. Moul Screening for prostate cancer in military populations Mil Med 170 2005 905 914 (Pubitemid 41627879)
23. J.W. Moul Population screening for prostate cancer and emerging concepts for young men Clin Prostate Cancer 2 2003 87 97 (Pubitemid 37296102)
24. P.H. Gann, C.H. Hennekens, and M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer JAMA 273 1995 289 294
25. U.H. Stenman, M. Hakama, and P. Knekt Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer Lancet 344 1994 1594 1598 (Pubitemid 24365358)
26. M. Bul, P.J. van Leeuwen, X. Zhu, F.H. Schröder, and M.J. Roobol Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam Eur Urol 59 2011 498 505
27. A.S. Whittemore, P.M. Cirillo, D. Feldman, and B.A. Cohn Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans J Urol 174 2005 872 876 discussion 876 (Pubitemid 41140619)
28. D.M. Preston, L.I. Levin, and D.J. Jacobson Prostate-specific antigen levels in young white and black men 20 to 45 years old Urology 56 2000 812 816
29. J.W. Moul Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials Urology 57 Suppl 1 2001 174 177 (Pubitemid 33733941)
30. J. Fang, E.J. Metter, and P. Landis Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging Urology 58 2001 411 416 (Pubitemid 32816360)
31. P. Tang, L. Sun, and M.A. Uhlman Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk J Urol 183 2010 946 950
32. D. Connolly, A. Black, A. Gavin, P.F. Keane, and L.J. Murray Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation Cancer Epidemiol Biomarkers Prev 17 2008 271 278 (Pubitemid 351272775)
33. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436 (Pubitemid 350002992)
34. H. Lilja, A.M. Cronin, and A. Dahlin Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 2011 1210 1219
35. S. Loeb, K.A. Roehl, and J.A. Antenor Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Urology 67 2006 316 320 (Pubitemid 43189848)
36. A.J. Vickers, A.M. Cronin, and T. Bjork Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study BMJ 341 2010 c4521
37. L.H. Kuller, A. Thomas, G. Grandits, and J.D. Neaton Elevated prostate-specific antigen levels up to 25 years prior to death from prostate cancer Cancer Epidemiol Biomarkers Prev 13 2004 373 377 (Pubitemid 38737461)
38. P. Tang, L. Sun, and M.A. Uhlman Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience Cancer 116 2010 4711 4717
39. C.D. Scales Jr. , J. Antonelli, L.H. Curtis, K.A. Schulman, and J.W. Moul Prostate-specific antigen screening among young men in the United States Cancer 113 2008 1315 1323
40. C.D. Scales Jr. , L.H. Curtis, and R.D. Norris Relationship between body mass index and prostate cancer screening in the United States J Urol 177 2007 493 498 (Pubitemid 46054013)
41. L.P. Wallner, A.V. Sarma, and M.M. Lieber Psychosocial factors associated with an increased frequency of prostate cancer screening in men ages 40 to 79 years: the Olmsted County study Cancer Epidemiol Biomarkers Prev 17 2008 3588 3592
42. W.A. Sakr, D.J. Grignon, and J.D. Crissman High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases In Vivo 8 1994 439 443
43. M. Yin, S. Bastacky, U. Chandran, M.J. Becich, and R. Dhir Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors J Urol 179 2008 892 895 discussion 895
44. G. Soos, I. Tsakiris, and J. Szanto The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study Eur Urol 48 2005 739 744 (Pubitemid 41495371)
45. A.V. Mitra, E.K. Bancroft, and Y. Barbachano Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study BJU Int 107 2011 28 39
46. H.B. Carter, A. Kettermann, and C. Warlick Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience J Urol 178 2007 2359 2364 discussion 2364-5
47. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 2011 1708 1717
48. S. Loeb, K.A. Roehl, B.T. Helfand, and W.J. Catalona Complications of open radical retropubic prostatectomy in potential candidates for active monitoring Urology 72 2008 887 891
49. A. Reissigl, J. Pointner, and W. Horninger Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study Urology 46 1995 662 665
50. P.J. van Leeuwen, D. Connolly, and T.L. Tammela Balancing the harms and benefits of early detection of prostate cancer Cancer 116 2010 4857 4865
51. L. Sun, J.W. Moul, and J.M. Hotaling Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years BJU Int 99 2007 753 757 (Pubitemid 46439564)
52. S. Loeb, K.A. Roehl, W.J. Catalona, and R.B. Nadler Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age? BJU Int 101 2008 817 821 (Pubitemid 351347735)
53. S. Loeb, R.B. Nadler, K.A. Roehl, J.A. Antenor, and W.J. Catalona Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median J Urol 177 2007 1745 1748 (Pubitemid 46578226)
54. E.D. Crawford, P.F. Pinsky, and D. Chia Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial J Urol 175 2006 1286 1290 discussion 1290
55. K.S. Ross, H.B. Carter, J.D. Pearson, and H.A. Guess Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection JAMA 284 2000 1399 1405